Shares of Hoth Therapeutics, Inc. (HOTH) are surging over 50% on Wednesday after the biopharmaceutical company said it has signed a production deal for cancer treatment.
HOTH is currently trading at $2.48, up $0.84 or 51.22%, on the Nasdaq.
Hoth Therapeutics announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Recently, Hoth requested a Pre-Investigational New Drug meeting to the FDA to discuss a proposed drug development program for the novel treatment.
HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor inhibitor therapy.
For comments and feedback: editorial@rttnews.com